Literature DB >> 2859463

Impaired human antibody response to the thymus-independent antigen, DNP-Ficoll, after splenectomy. Implications for post-splenectomy infections.

P L Amlot, A E Hayes.   

Abstract

A synthetic thymus-independent (TI) antigen, dinitrophenyl-'Ficoll', was used to immunise controls, untreated patients with Hodgkin's disease (HD), and patients who had had splenectomy (most for staging in HD). The antibody response to DNP-ficoll was much lower in splenectomised patients than in the other groups and the antibody titres 7, 14, and 21 days after immunisation of splenectomised patients were approximately a tenth of the titres in the other groups. In contrast patients who had been primed with DNP-ficoll before splenectomy responded normally to re-immunisation 6-28 months after splenectomy. These results suggest that the antibody response upon first exposure to certain TI antigens occurs mainly in the spleen. Antibody responses are not generally impaired in splenectomised patients immunised with pneumococcal or other bacterial polysaccharides, probably because natural exposure and priming by these TI antigens before splenectomy are widespread. However, such patients must be vulnerable to overwhelming infection by encapsulated bacteria not met before splenectomy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859463     DOI: 10.1016/s0140-6736(85)91613-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  46 in total

Review 1.  Clinical implications of the specialised B cell response to polysaccharide encapsulated pathogens.

Authors:  C G Vinuesa; C de Lucas; M C Cook
Journal:  Postgrad Med J       Date:  2001-09       Impact factor: 2.401

2.  Impaired proliferative responses of peripheral blood B cells from splenectomized subjects to phorbol ester and ionophore.

Authors:  P N Foster; L K Trejdosiewicz
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

3.  Characterization of two monoclonal antibodies (UCL4D12 and UCL3D3) that discriminate between human mantle zone and marginal zone B cells.

Authors:  J Smith-Ravin; J Spencer; P C Beverley; P G Isaacson
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

Review 4.  Phenotypic and functional heterogeneity of human memory B cells.

Authors:  Iñaki Sanz; Chungwen Wei; F Eun-Hyung Lee; Jennifer Anolik
Journal:  Semin Immunol       Date:  2008-02-06       Impact factor: 11.130

5.  Comparing CDRH3 diversity captured from secondary lymphoid organs for the generation of recombinant human antibodies.

Authors:  Sophie Venet; Marie Kosco-Vilbois; Nicolas Fischer
Journal:  MAbs       Date:  2013-07-02       Impact factor: 5.857

Review 6.  The splenic marginal zone in humans and rodents: an enigmatic compartment and its inhabitants.

Authors:  Birte Steiniger; Eva Maria Timphus; Peter J Barth
Journal:  Histochem Cell Biol       Date:  2006-07-01       Impact factor: 4.304

7.  Human immune responses in vivo to protein (KLH) and polysaccharide (DNP-Ficoll) neoantigens: normal subjects compared with bone marrow transplant patients on cyclosporine.

Authors:  P L Amlot; A E Hayes; D Gray; E C Gordon-Smith; J H Humphrey
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

8.  Immunoarchitecture of regenerated splenic transplants: influence of donor and host age on the regeneration of splenic compartments.

Authors:  J Westermann; P Peschel; R Pabst
Journal:  Cell Tissue Res       Date:  1988-11       Impact factor: 5.249

9.  Splenic autotransplantation and the immune system. Adequate testing required for evaluation of effect.

Authors:  W Timens; R Leemans
Journal:  Ann Surg       Date:  1992-03       Impact factor: 12.969

10.  Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy.

Authors:  J J Ballet; G Sulcebe; L J Couderc; F Danon; C Rabian; M Lathrop; J P Clauvel; M Seligmann
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.